In my post "The German UPCA Ratification - at Schweinsgalopp towards Mautdebakel" on this blog, I cautioned the German Ministry of Justice and Consumer Protection against ignoring the apparent…
In an earlier post we considered the general licensing and evaluation issues raised by a report issued in January 2021 by the EU Group of Experts on Standard Essential Patents (EU SEPs Expert Group…
At the beginning of the year, the Russian Government granted the first compulsory license on a series of Big Pharma's patents.
For the first time ever, "public security” clause has been evoked…
As of February 2021, it is still too early to have a clear and complete view of how the COVID-19 health, economic, and social crisis has affected patent filing trends and how innovation specifically…
The report issued in January 2021 by the EU Group of Experts on Licensing and Valuation of Standard Essential Patents (EU SEPs Expert Group) was long-anticipated and followed two years of debate and…
Normal service looks to have been resumed following the Court of Appeal judgment in IPCom v Vodafone [2021] EWCA Civ 205, in which Arnold LJ reversed a first instance finding by Recorder Douglas…
Neither of French case law nor of a mood note on a general theme today, like Werther I prefer to suffer with my eternal love for Goethe's language to evoke the Sisvel vs Haier II decision (FRAND-…
From time to time, one may find publications that seek to explore the influence that the Bible may have had on patent law. A classic example is Exodus 20:15: "You shall not steal." Another sometimes-…
Biologic drugs, many of which are antibodies, represent an increasing share of the pharmaceutical market. In recent years, numerous broad functional patent claims directed at therapeutic antibodies…
For the second time, I will have the pleasure and the Honor of welcoming Professor Anne-Catherine Chriariny. Professor Chiariny teaches Patent Law and International Private Law at the University of…
